Kakehi Ryo, Kobayashi Hiroki, Mashiyama Haruna, Yajima Tatsuo, Koyama Hiroo, Ito Takashi K, Yoshida Minoru, Nagaoka Yasuo, Sumiyoshi Takaaki
Department of Life Science and Biotechnology, Faculty of Chemistry, Materials and Bioengineering, Kansai University, 3-3-35 Yamate-cho, Suita, Osaka 564-8680, Japan.
Laboratory of Oncology, School of Life Sciences, Tokyo University of Pharmacy and Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo 192-0392, Japan.
ACS Med Chem Lett. 2024 Dec 4;16(1):59-63. doi: 10.1021/acsmedchemlett.4c00436. eCollection 2025 Jan 9.
Inhibiting phosphofructokinase-1 (PFK1) is a promising approach for treating lactic acidosis and mitochondrial dysfunction by activating oxidative phosphorylation. Tryptolinamide (TLAM) has been shown as a PFK1 inhibitor, but its complex stereochemistry, with 16 possible isomers complicates further development. We conducted an asymmetric synthesis, determined the absolute configurations, and evaluated the PFK1 inhibitory activity of the TLAM isomers. Our structure-activity relationship (SAR) study of TLAM isomers revealed that both carboline and norbornene configurations influence PFK1 inhibitory activity. Among isomers -, compound was the most potent PFK1 inhibitor. Our elucidation of the SAR information on PFK1 inhibitors provides valuable insights for effective optimization.
抑制磷酸果糖激酶-1(PFK1)是一种通过激活氧化磷酸化来治疗乳酸性酸中毒和线粒体功能障碍的有前景的方法。色胺酰胺(TLAM)已被证明是一种PFK1抑制剂,但其复杂的立体化学结构,有16种可能的异构体,使进一步开发变得复杂。我们进行了不对称合成,确定了绝对构型,并评估了TLAM异构体的PFK1抑制活性。我们对TLAM异构体的构效关系(SAR)研究表明,咔啉和降冰片烯构型均影响PFK1抑制活性。在异构体中,化合物是最有效的PFK1抑制剂。我们对PFK1抑制剂的SAR信息的阐明为有效优化提供了有价值的见解。